行情

CHMA

CHMA

Chiasma
NASDAQ

实时行情|Nasdaq Last Sale

3.400
-0.030
-0.87%
交易中 15:26 04/02 EDT
开盘
3.400
昨收
3.430
最高
3.450
最低
3.360
成交量
13.85万
成交额
--
52周最高
9.25
52周最低
2.880
市值
1.44亿
市盈率(TTM)
-3.1150
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CHMA价格均价为13.40,最高价位18.00,最低价为10.00。

EPS

CHMA 新闻

更多
  • 特朗普称沙特和俄罗斯同意减产约1000万桶 但消息未获沙特证实
  • 新浪美股 · 1小时前
  • 特朗普宣称石油减产遭“打脸” 油价经历过山车行情
  • 新浪财经-自媒体综合 · 1小时前
  • 午后:油价大起大落 美股涨幅收窄
  • 新浪美股 · 1小时前
  • 美联储Kashkari称美国经济“几乎肯定”正陷入衰退
  • 新浪美股 · 1小时前

所属板块

制药
+1.89%
制药与医学研究
+1.93%

热门股票

代码
价格
涨跌幅

CHMA 简况

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
展开

微牛提供Chiasma Inc(NASDAQ-CHMA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CHMA股票新闻,以帮助您做出投资决策。